Toll-like receptor 4–Myeloid differentiation factor 2 complex (TLR4–MD-2) (TLR4–MD-2)

The Toll-like receptor 4–Myeloid differentiation factor 2 (TLR4–MD-2) complex is the primary innate immune sensor for lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria [PMID: 19219023]. TLR4 is a transmembrane protein that requires the non-covalently associated extracellular protein MD-2 (also known as LY96) to effectively bind LPS and initiate downstream signaling [UniProt: P33765, Q9Y6Y9]. Upon LPS binding, the TLR4–MD-2 complex undergoes a conformational change leading to the formation of a symmetrical heterodimer, which serves as a platform for intracellular signaling [PMID: 20303873]. This dimerization recruits adapter proteins such as MyD88 and TRIF, ultimately triggering the activation of NF-κB and IRF3 pathways to produce pro-inflammatory cytokines and Type I interferons [PMID: 25735460]. While essential for host defense against pathogens, excessive or dysregulated activation of the TLR4–MD-2 complex is a central driver of septic shock, acute lung injury, and various chronic inflammatory diseases [PMID: 30107140]. In the context of drug development, the complex is targeted by antagonists like Eritoran and TAK-242, which aim to mitigate systemic inflammation in conditions like sepsis [PMID: 23471844]. Conversely, TLR4–MD-2 agonists such as Monophosphoryl lipid A (MPLA) are utilized as potent vaccine adjuvants to enhance the magnitude and quality of the adaptive immune response [PMID: 23865914]. The complex also plays emerging roles in non-infectious pathologies, including neuropathic pain and metabolic syndrome, expanding its relevance as a therapeutic target [PMID: 24035186].

Other names

TLR4/MD-2 complexCD284/LY96 complexToll-like receptor 4/Lymphocyte antigen 96 complexLPS receptor complexTLR4-MD2 heterodimer

Antagonism of the LPS-binding site on MD-2 or the TLR4 dimerization interface to inhibit pro-inflammatory signaling; or agonism to stimulate immune responses for vaccine efficacy.